Hematology-Oncology
Latest news
316 articles · 20 / page
MRD-Guided Intensification: A Tailored Approach to First-Line Chronic Lymphocytic Leukaemia Treatment
The HOVON 158/NEXT STEP phase 2 trial demonstrates that a measurable residual disease (MRD)-guided intensification strategy using ibrutinib and obinutuzumab significantly deepens remissions in first-line CLL patients who do not achieve deep
Fixed-Duration Therapy Challenging the Continuous Paradigm in Chronic Lymphocytic Leukemia: Insights from the CLL17 Trial
The Phase 3 CLL17 trial demonstrates that fixed-duration venetoclax-based regimens are noninferior to continuous ibrutinib in previously untreated CLL, offering deep molecular responses and comparable progression-free survival while allowin
Comprehensive Summary of Talquetamab Monotherapy and Combination Therapy in Relapsed or Refractory Multiple Myeloma
Talquetamab, alone or combined with teclistamab, shows promising efficacy in treating relapsed/refractory multiple myeloma, including extramedullary disease, though high-grade adverse events are common but manageable.
Five-Year Durability of Etranacogene Dezaparvovec: Redefining the Long-term Management of Hemophilia B
The final 5-year analysis of the HOPE-B trial confirms that etranacogene dezaparvovec provides stable, long-term factor IX expression and clinical protection for patients with hemophilia B, effectively eliminating the need for routine proph
Precision Gene Correction via Prime Editing Restores NADPH Oxidase Activity in Patients with p47phox-Deficient Chronic Granulomatous Disease
A Phase 1/2 clinical trial demonstrates that PM359, an autologous prime-edited CD34+ cell therapy, successfully corrects the delGT mutation in NCF1, restoring essential microbicidal function in patients with p47-CGD without the off-target r
Precision Base-Editing and Universal CAR7 T Cells: Transforming the Treatment Landscape for Refractory T-Cell Acute Lymphoblastic Leukemia
Recent clinical trials demonstrate the rapid evolution of CD7-targeted CAR T-cell therapies. From donor-derived models to universal base-edited cells, these innovations offer high remission rates and a viable bridge to transplant for patien
Short-Course Ianalumab Combined with Eltrombopag: A Potential Shift Toward Sustained Remission in Immune Thrombocytopenia
The VAYHIT2 Phase 3 trial demonstrates that adding the BAFF-R monoclonal antibody ianalumab to eltrombopag significantly extends treatment-free intervals and improves stable response rates in patients with relapsed or refractory immune thro
B-Cell Depletion Meets TPO-RA: Ianalumab and Eltrombopag Redefine Treatment Success in Immune Thrombocytopenia
The Phase 3 VAYHIT2 trial reveals that combining ianalumab with eltrombopag significantly extends freedom from treatment failure and increases stable response rates in patients with second-line immune thrombocytopenia, potentially offering
Teclistamab plus Daratumumab Redefines Outcomes in Relapsed or Refractory Multiple Myeloma: A Paradigm Shift in Early-Line Intervention
The phase 3 MajesTEC-3 trial demonstrates that combining teclistamab with daratumumab significantly extends progression-free survival compared to standard therapies in patients with relapsed or refractory multiple myeloma, achieving high ra
Validated PRESEV Score Identifies Adults with Sickle Cell VOC at Low Risk for Acute Chest Syndrome — Implications for Safer Outpatient Management
An international prospective validation confirms the PRESEV score reliably identifies adult sickle cell patients hospitalized for vaso-occlusive crisis (VOC) who are at low risk for acute chest syndrome (ACS), enabling safer outpatient mana
Rising Immunotherapy Use at Cancer End of Life Is Linked to More Hospital-Based Care: What Clinicians Need to Know
In a population-based Ontario study, use of systemic anticancer therapy (SACT) in the last 30 days of life increased—driven by immunotherapy—and was associated with higher emergency visits, hospitalizations, ICU admissions, and hospital dea
Rising Use of Novel Systemic Anticancer Therapies at End of Life Is Associated With More Hospital-Based Care
Use of systemic anticancer therapy in the last 30 days of life rose from 2015–2020, mainly due to immunotherapy; any SACT was linked to more than twofold higher odds of multiple ED visits, hospitalizations, ICU admission, and in-hospital de
Systemic Anticancer Therapy in the Last 30 Days of Life Is Tied to More Acute Care and Less Hospice Use in Older Adults: A SEER–Medicare Analysis
A SEER–Medicare study of 315,089 older adults found that systemic anticancer therapy within 30 days of death—whether cytotoxic, targeted, immunotherapy, or combinations—was associated with substantially higher acute care use and lower hospi
Ziftomenib Shows Clinically Meaningful Activity in Heavily Pretreated NPM1‑Mutated AML — A Targeted Option for a Molecularly Defined Relapse Population
In the phase II registration cohort of KOMET‑001, oral menin inhibitor ziftomenib achieved a CR/CRh rate of 22% (61% MRD negativity) and an ORR of 33% in relapsed/refractory NPM1‑mutated AML with manageable toxicity, supporting further stud
Restrictive versus Liberal Transfusion Thresholds in Very Low Birthweight Infants: Fewer Transfusions Without Harm to Survival or Early Neurodevelopment
A Cochrane meta-analysis of six RCTs (3,451 infants) finds restrictive hemoglobin thresholds reduce transfusion exposure modestly with no detectable effect on mortality or neurodevelopmental impairment at 18–26 months.
Donor-Search Prognosis Strategy Yields Comparable 2-Year Survival After Alternative-Donor Allogeneic Transplantation
BMT CTN 1702 shows that prioritizing alternative donors for patients unlikely to find a matched unrelated donor achieves similar 2‑year survival and transplant outcomes versus patients likely to find a matched unrelated donor.
Platelet Transfusion in the ICU: Rare But Variable — A 30-Country Prospective Cohort Reveals Wide Practice Differences
An international prospective cohort found platelet transfusions were used in 6% of ICU patients, mostly for bleeding or prophylaxis, with wide variation in thresholds and adherence across geo-economic regions, highlighting need for stewards
RBC Transfusions in Early Sepsis Resuscitation: Common, Complex, and Potentially Harmful Above a 10 g/dL Threshold
In a multicenter Korean sepsis cohort, early RBC transfusions were frequent and driven by illness severity. No overall 60‑day mortality difference was seen after propensity matching, but transfusion was associated with harm at hemoglobin ≥1
Five-Year POLARIX Follow-Up: Polatuzumab-R-CHP Improves Long-Term PFS in Frontline DLBCL — What Clinicians Need to Know
At five years, pola‑R‑CHP showed a sustained progression‑free survival benefit versus R‑CHOP in newly diagnosed intermediate‑/high‑risk DLBCL (HR 0.77), with similar long‑term tolerability and no statistically significant overall survival d
Mosunetuzumab + Polatuzumab Vedotin Outperforms R‑GemOx in Transplant‑Ineligible Relapsed/Refractory Large B‑Cell Lymphoma: Primary Results of the Phase III SUNMO Trial
In the randomized phase III SUNMO trial, mosunetuzumab plus polatuzumab vedotin significantly improved response rates and progression‑free survival versus R‑GemOx in transplant‑ineligible relapsed/refractory large B‑cell lymphoma, with low
Browse by specialty
Open language-specific specialty feeds and department pages.